Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > Something is coming for Kly- COVID News?
View:
Post by BYLowSELHIGH on Apr 27, 2020 3:40pm

Something is coming for Kly- COVID News?

All COVID stocks flying ....investors will tear all walls if a COVID News comes for kly
Comment by Theknocker91 on Apr 27, 2020 4:33pm
The only thing they have related to covid 19 is an ARDS treatment method with cbd aerosol, but I dont think they've done anything with it in years.
Comment by Moonshiner592 on Apr 27, 2020 4:48pm
  Of course!... if they get that K-1012 in the next NR as an aid for COVID? ... we'll be taking off in no time ... but will they do it?  .. that the big question here.. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities